// App-Quantinova.ai

3222 : Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study

Researchers

Presenter

  • Chris Chamberlain

Principal Investigators

  • Murray Urowitz

  • Julie Soranson

  • Mark Watling

  • Peter Colman

  • Olivier Harari

  • Thomas Dorner

  • Falk Hiepe

Medical Centers

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada

  • University of Toronto, Toronto, ON, Canada

Locations

  • Germany

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Urology

Disease

  • Lupus

  • Glomerulonephritis

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Dapirolizumab pegol

Outcome

  • N/A

Study Design

  • randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved